IMBRUVICA® + venetoclax work together to achieve a durable and sustained response[1][2][3][4]
Learn how these two targeted therapies reinforce each other’s mechanism of action (MoA) in the video animation below
Video Not Published
IMBRUVICA® + venetoclax: strength through synergy
Distinct, complementary and synergistic MoA results in disease clearance across multiple compartments, and deep, durable responses that prolong PFS[1][2][3][4][5][6]*
Adapted from Moreno C, et al. 2022.
What benefits does the mechanism of action offer your patients?
Leading experts discuss the distinct MoA of IMBRUVICA® + venetoclax combination therapy
GLOW clinical trial
A Phase III study evaluating the efficacy and safety of first-line IMBRUVICA® + venetoclax combination therapy in patients with CLL who are older and/or have comorbidities[4]
CAPTIVATE clinical trial
An international multicentre Phase II study evaluating the IMBRUVICA® + venetoclax combination therapy in previously untreated CLL patients aged ≤70 years[5]
IMBRUVICA® + venetoclax in CLL
IMBRUVICA® + venetoclax efficacy
*Prolongs PFS vs Clb+O.[4][6]
BCL-2=B-cell lymphoma 2; BTK=Bruton's tyrosine kinase; Clb+O=chlorambucil + obinutuzumab; CLL=chronic lymphocytic leukaemia; FD=fixed duration; MoA=mechanism of action; PFS=progression-free survival.
| Adverse events should be reported. Reporting an adverse event will help J&J monitor the safety of all our healthcare products for the benefit of patients and consumers. It is important to report adverse events, even if it is a known adverse event, as this provides valuable information for monitoring product safety, allowing J&J to provide up-to-date information in the Summary of Product Characteristics and product information leaflets. For Adverse Events or safety related issues on J&J products, please approach the mailbox PVNEMA@ITS.JNJ.COM or Tel: +961 1 518769/ +961 1 518775 |
CP-352641 - CP-352642 - October 2022
Johnson & Johnson Innovative Medicine NV